1. Home
  2. CYTK vs KNSA Comparison

CYTK vs KNSA Comparison

Compare CYTK & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$56.27

Market Cap

7.8B

Sector

Health Care

ML Signal

N/A

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

N/A

Current Price

$96.22

Market Cap

7.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYTK
KNSA
Founded
1997
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
7.7B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
CYTK
KNSA
Price
$56.27
$96.22
Analyst Decision
Buy
Strong Buy
Analyst Count
22
7
Target Price
$109.42
★ $109.43
AVG Volume (30 Days)
★ 1.9M
943.8K
Earning Date
11-04-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 225.00
EPS
N/A
★ 1.14
Revenue
$13,368,000.00
★ $677,564,000.00
Revenue This Year
$87.17
$54.96
Revenue Next Year
$170.90
$24.16
P/E Ratio
★ N/A
$84.26
Revenue Growth
N/A
★ 60.09
52 Week Low
$53.58
$37.02
52 Week High
$88.31
$99.31

Technical Indicators

Market Signals
Indicator
CYTK
KNSA
Relative Strength Index (RSI) 38.80 59.87
Support Level N/A $72.76
Resistance Level $66.62 $98.48
Average True Range (ATR) 2.69 5.13
MACD -0.24 0.28
Stochastic Oscillator 24.29 80.18

Price Performance

Historical Comparison
CYTK
KNSA

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: